Aura Biosciences
Intraocular nanoparticles that deliver targeted therapy to solid tumors, initially for choroidal melanoma
- Sector
- Biotech
- Headquarters
- CAMBRIDGE, MA
- Founded
- 2009
- Latest Form D
- $80.5M, Apr 2021
- Total capital
- $179M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $179M
- 11 Form D · last Apr 2021
- 67 months since last filing
- Federal contracts
- $198K
- 1 award · Health and Human S
- Rank in Biotech#296 of 4373
- Granted patents
- 6
- 15 pending · first 2017
- Rank in peer group#245 of 1449
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 11th filing$80.5M
- Private capital raisedForm D · SEC · 10th filing$10M
- Private capital raisedForm D · SEC · 9th filing$20M
- Private capital raisedForm D · SEC · 8th filing$32.4M
- Private capital raisedForm D · SEC · 7th filing$1.8M
- Private capital raisedForm D · SEC · 6th filing$21M
- Private capital raisedForm D · SEC · 5th filing$4M
- Private capital raisedForm D · SEC · 4th filing$1.3M
- Private capital raisedForm D · SEC · 3rd filing$3.2M
- Private capital raisedForm D · SEC · 2nd filing$2.9M
- Private capital raisedForm D · SEC · 1st filing$1.4M
Show 1 earlier federal award
- Federal contractHealth and Human S · Igf::ot::igf - Treatment Of Hpv+ Head And Neck Cancer With Sirna Nanosphere Particles$198K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 1449 peers
Line = medianBiotech · Molecule
- Granted patents#245 · top 17%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
From SEC Form D filings- Alan WaltsDirectorNamed in SEC Form D filings
- Alan E. Walts, Ph.D.DirectorNamed in SEC Form D filings
- Art PappasDirectorNamed in SEC Form D filings
- Casper E. BreumDirectorNamed in SEC Form D filings
- Christian SchetterDirectorNamed in SEC Form D filings
- Dale E. Pfost, Ph.D.DirectorNamed in SEC Form D filings
Show all 29 people
- David JohnsonDirectorNamed in SEC Form D filings
- Edmundo Muniz, M.D., Ph.D.DirectorNamed in SEC Form D filings
- Elisabet de los Pinos, Ph.D.Executive Officer, DirectorNamed in SEC Form D filings
- George Golumbeski, Ph.D.DirectorNamed in SEC Form D filings
- Giovanni Mariggi, Ph.D.DirectorNamed in SEC Form D filings
- Henri E. TermeerDirectorNamed in SEC Form D filings
- Israel RuizDirectorNamed in SEC Form D filings
- Javier GarciaDirectorNamed in SEC Form D filings
- Joel E. Jean-Mairet, Ph.D.DirectorNamed in SEC Form D filings
- Jose Baselga, Ph.D.DirectorNamed in SEC Form D filings
- Jose' E. Baselga, Ph.D.DirectorNamed in SEC Form D filings
- Julie E. FederExecutive OfficerNamed in SEC Form D filings
- Karan TakharDirectorNamed in SEC Form D filings
- Lawrence C. BestDirectorNamed in SEC Form D filings
- Lewis E. GeffenExecutive OfficerNamed in SEC Form D filings
- Mark E. ChinDirectorNamed in SEC Form D filings
- Michael E. WyzgaExecutive OfficerNamed in SEC Form D filings
- Pedro GranadilloDirectorNamed in SEC Form D filings
- Peter B. FinnExecutive OfficerNamed in SEC Form D filings
- Peter B. WirthDirectorNamed in SEC Form D filings
- Raj Parekh, Ph.D.DirectorNamed in SEC Form D filings
- Salvador Garcia-AtanceDirectorNamed in SEC Form D filings
- Sebastian C. JuliaDirectorNamed in SEC Form D filings
What it has protected
USPTO · 6 granted of 21- PendingMethods And Compositions For Producing A Therapeutic Field EffectUSPTOApplication 19359229
- PendingHuman Papillomavirus Nanoparticle FormulationsUSPTOApplication 17442277
- GrantedHpv Particles And Uses ThereofUSPTOUS 10,688,172
Show all 21 patent records
- Methods And Compositions For Producing A Therapeutic Field EffectApr 16, 2026 · Application 19359229Pending
- Human Papillomavirus Nanoparticle FormulationsMay 19, 2022 · Application 17442277Pending
- Hpv Particles And Uses ThereofJun 23, 2020 · US 10,688,172Granted
- Virion-derived Nanospheres For Selective Delivery Of Therapeutic And Diagnostic Agents To Cancer CellsMar 24, 2020 · US 10,596,275Granted
- Virion-derived Nanospheres For Selective Delivery Of Therapeutic And Diagnostic Agents To Cancer CellsMay 28, 2019 · US 10,300,150Granted
- Hpv Particles And Uses ThereofJan 15, 2019 · US 10,179,168Granted
- Virion-derived Nanospheres For Selective Delivery Of Therapeutic And Diagnostic Agents To Cancer CellsJan 2, 2018 · US 9,855,347Granted
- Virion-derived Nanospheres For Selective Delivery Of Therapeutic And Diagnostic Agents To Cancer CellsJul 11, 2017 · US 9,700,639Granted
- Bladder Cancer TherapiesApplication 63241776Pending
- Human Papillomavirus Nanoparticle FormulationsApplication PCTUS2020024684Pending
- Virus-like Particle Drug Conjugate FormulationsApplication 62824227Pending
- Virion-derived Nanospheres For Selective Delivery Of Therapeutic And Diagnostic Agents To Cancer CellisApplication PCTUS2013025230Pending
- Virion Derived Protein Nanoparticles For Delivering Radioisotopes For The Diagnosis And Treatment Of Malignant And Systemic Disease And The Monitoring Of TherapyApplication PCTUS2012063603Pending
- Hpv Particles And Uses ThereofApplication PCTUS2009004299Pending
- Methods And Compositions For Producing A Therapeutic Field EffectApplication PCTUS2025051057Pending
- Methods And Compositions For Producing A Therapeutic Field EffectApplication 63794556Pending
- Methods And Compositions For Producing A Therapeutic Field EffectApplication 63774561Pending
- Methods And Compositions For Producing A Therapeutic Field EffectApplication 63743688Pending
- Methods And Compositions For Producing A Therapeutic Field EffectApplication 63724011Pending
- Urothelial Cancer TherapiesApplication 63708172Pending
- Bladder Cancer TherapiesApplication PCTUS2022042693Pending
Related companies, and why
- Avidity BiosciencesSimilar federal contract value in Biotech · $200K in contracts
- TARGEPEUTICS, INC.Similar federal contract value in Biotech · $200K in contracts
- Celldex TherapeuticsSimilar federal contract value in Biotech · $199K in contracts
- GEOVAX, INC.Similar federal contract value in Biotech · $198K in contracts
- Angiocrine BioscienceSimilar federal contract value in Biotech · $189K in contracts
- Tenax TherapeuticsSimilar federal contract value in Biotech · $185K in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .